Drugs Made In America Acquisition Corp.

We are a blank check company incorporated in the Cayman Islands as an exempted company. Our purpose is to complete a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. We have not engaged in any operations or generated any revenue to date. As defined under the Securities Exchange Act of 1934, as amended, we are a "shell company" because we have no operations and nominal assets, consisting almost entirely of cash. On June 17, 2024, we issued 22,361,111 ordinary shares, referred to as "founder shares," to Drugs Made In America Acquisition LLC, our sponsor, for a total purchase price of $35,000, or approximately $0.0016 per share. On November 6, 2024, our sponsor surrendered and forfeited 12,503,968 ordinary shares to us without consideration, leaving 9,857,143 founder shares. Before our sponsor's initial investment of $35,000, we had no assets, tangible or intangible. On January 29, 2025, we completed our initial public offering (IPO) of 20,000,000 units. Each unit consists of one ordinary share and one right to receive one-eighth (1/8) of one ordinary share upon the completion of an initial business combination. The units were sold at an offering price of $10.00 per unit, generating gross proceeds of $200,000,000 before expenses. We also granted the underwriters a 45-day option to purchase up to 3,000,000 additional units. Concurrently with the IPO closing, we completed a private placement with our sponsor of 400,000 units at $10.00 per unit, totaling $4,000,000.